Laboratory and Clinical Medicine. Pharmacy

Scientific and practical quarterly peer-reviewed journal

ISSN 2712-9330 (Online)

THE PULMONARY MICROBIOME AS A RISK FACTOR FOR LUNG CANCER DEVELOPMENT AND PROGRESSION. REVIEW

Details
Hits: 842
Autors:

Kireev A. A. , Gorbanev A. I.

  • Continuous numbering: 6
  • Pages: 51-58
  • Share:

Heading: Abstract Reviews

Lung cancer, being one of the leading causes of mortality among cancer patients, is a global medical and social problem. The number of studies devoted to the etiology, molecular pathology and methods of early detection of lung neoplasms has been steadily increasing. Recently, the great efforts are made to search for alternative methods of diagnosis, therapy and prevention of neoplasms of the respiratory system. So the study of the influence of the quantitative and qualitative microbiome characteristics on the growth and tumor development has become increasingly relevant. This review is devoted to the association between the composition of the pulmonary microbiome and the development of malignant neoplasms of the lungs. We used the analysis of the available literature data to perform this review.

Andrey A. Kireev – MD, PhD, cytologist, Diagnostic Laboratory, City Clinical Hospital named after S. S. Yudin of the Department of Health of the City of Moscow, Moscow, Russia; lecturer, International Cytology School & Innovatory Medical School. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Alexandr I. Gorbanev – cytologist, Diagnostic Laboratory, City Clinical Hospital named after S. S. Yudin of the Department of Health of the City of Moscow, Russia; resident of pathology department, Moscow State Medical and Dental University of A. I. Evdokimov, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it..

1. Abudureheman M, Simayi R, Aimuroula H, et al. Association of Mycobacterium tuberculosis L-formmpb64 gene and lung cancer. Eur Rev Med Pharmacol Sci. 2019;23(1):113-20. DOI: 10.26355/eurrev_201901_16755
2. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Published 2015 Mar 14;385(9972):946]. Lancet.
3. Bello S, Vengoechea JJ, Ponce-Alonso M, et al. Core Microbiota in Central Lung Cancer with Streptococcal Enrichment as a Possible Diagnostic Marker. Arch Bronconeumol. 2021;57(11):681-9. DOI: 10.1016/j.arbr.2020.05.017
4. Bingula R, Filaire E, Molnar I, et al. Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial. Respir Res. 2020;21(1):129. Published 2020 May 25. DOI: 10.1186/s12931-020-01392-2
5. Brenner DR, Boffetta P, Duell EJ, et al. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol. 2012;176(7):573-85. DOI: 10.1093/aje/kws151
6. Chang YS, Hsu MH, Tu SJ, et al. Metatranscriptomic Analysis of Human Lung Metagenomes from Patients with Lung Cancer. Genes (Basel). 2021;12(9):1458. Published 2021 Sep 21. DOI: 10.3390/genes12091458
7. Cooper AM, Khader SA. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev. 2008;226:191-204. DOI: 10.1111/j.1600-065X.2008.00702.x
8. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7. DOI: 10.1038/nature01322
9. Denholm R, Sch?z J, Straif K, et al. Is previous respiratory disease a risk factor for lung cancer?. Am J Respir Crit Care Med. 2014;190(5):549-59. DOI: 10.1164/rccm.201402-0338OC
10. Dheda K, Booth H, Huggett JF, et al. Lung remodeling in pulmonary tuberculosis. J Infect Dis. 2005;192(7):1201-9. DOI: 10.1086/444545
11. Dong H, Tan Q, Xu Y, et al. Convergent alteration of lung tissue microbiota and tumor cells in lung cancer. iScience. 2021;25(1):103638. Published 2021 Dec 16. DOI: 10.1016/j.isci.2021.103638
12. Dong Q, Chen ES, Zhao C, Jin C. Host-Microbiome Interaction in Lung Cancer. Front Immunol. 2021;12:679829. Pub-lished 2021 May 24. DOI: 10.3389/fimmu.2021.679829
13. Engels EA, Shen M, Chapman RS, et al. Tuberculosis and subsequent risk of lung cancer in Xuanwei, China. Int J Cancer. 2009;124(5):1183-7. DOI: 10.1002/ijc.24042
14. Garrido-Mart?n EM, Paz-Ares L. Lung Cancer and Microbiome. Arch Bronconeumol (Engl Ed). 2020;56(1):3-4. DOI: 10.1016/j.arbres.2019.04.012
15. Goto T. Airway Microbiota as a Modulator of Lung Cancer. Int J Mol Sci. 2020;21(9):3044. Published 2020 Apr 26. DOI: 10.3390/ijms21093044
16. Goto T. Microbiota and lung cancer. Semin Cancer Biol. 2022;86(Pt 3):1-10. DOI: 10.1016/j.semcancer.2022.07.006
17. Guo H, Zhao L, Zhu J, et al. Microbes in lung cancer initiation, treatment, and outcome: Boon or bane? Semin Cancer Biol. 2022;86(Pt 2):1190-206. DOI: 10.1016/j.semcancer.2021.05.025
18. Hong S, Mok Y, Jeon C, et al. Tuberculosis, smoking and risk for lung cancer incidence and mortality. Int J Cancer. 2016;139(11):2447-55. DOI: 10.1002/ijc.30384
19. Huang DH, He J, Su XF, et al. The airway microbiota of non-small cell lung cancer patients and its relationship to tumor stage and EGFR gene mutation. Thorac Cancer. 2022;13(6):858-69. DOI: 10.1111/1759-7714.14340
20. Kim K, Kwon O, Ryu TY, et al. Propionate of a microbiota metabolite induces cell apoptosis and cell cycle arrest in lung cancer. Mol Med Rep. 2019; 20(2):1569-74. DOI: 10.3892/mmr.2019.10431
21. Kovaleva OV, Romashin D, Zborovskaya IB, et al. Human Lung Microbiome on the Way to Cancer. J Immunol Res. 2019;29:1394191. Published 2019 Jul 29. DOI: 10.1155/2019/1394191
22. Leng Q, Holden VK, Deepak J, et al. Microbiota Bi-omarkers for Lung Cancer. Diagnostics (Basel). 2021;11(3):407. Published 2021 Feb 27. DOI: 10.3390/diagnostics11030407
23. Lienhardt C, Fielding K, Sillah JS, et al. Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa. Int J Epidemiol. 2005;34(4):914-9. DOI: 10.1093/ije/dyi100
24. Lung Microbiota Promote Lung Cancer. Cancer Discov. 2019;9(4):458. DOI: 10.1158/2159-8290.CD-NB2019-019
25. Martins D, Mendes F, Schmitt F. Microbiome: A Supportive or a Leading Actor in Lung Cancer?. Pathobiology. 2021;88(2):198-207. DOI: 10.1159/000511556
26. Molina-Romero C, Arrieta O, Hern?ndez-Pando R. Tuberculosis and lung cancer. Tuberculosis y c?ncer de pulm?n. Salud Publica Mex. 2019;61(3):286-91. DOI: 10.21149/10090
27. Najafi S, Abedini F, Azimzadeh Jamalkandi S, et al. The composition of lung microbiome in lung cancer: a systematic review and meta-analysis. BMC Microbiol. 2021;21(1):315. Published 2021 Nov 11. DOI: 10.1186/s12866-021-02375-z
28. Oc?riz-D?ez M, Cruellas M, Gasc?n M, et al. Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy. Front Oncol. 2020;10:568939. Published 2020 Sep 24. DOI: 10.3389/fonc.2020.568939
29. Peters BA, Hayes RB, Goparaju C, et al. The Microbiome in Lung Cancer Tissue and Recurrence-Free Survival. Cancer Epidemiol Biomarkers Prev. 2019;28(4):731-40. DOI: 10.1158/1055-9965.EPI-18-0966
30. Ram?rez-Labrada AG, Isla D, Artal A, et al. The Influ-ence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy. Trends Cancer. 2020;6(2):86-97. DOI: 10.1016/j.trecan.2019.12.007
31. Reinhold L, M?llering A, Wallis S, et al. Dissimilarity of Airway and Lung Tissue Microbiota in Smokers undergoing Surgery for Lung Cancer. Microorganisms. 2020;8(6):794. Pub-lished 2020 May 26. DOI: 10.3390/microorganisms8060794
32. Riley DR, Sieber KB, Robinson KM, et al. Bacteria-human somatic cell lateral gene transfer is enriched in cancer samples. PLoS Comput Biol. 2013;9(6):e1003107. DOI: 10.1371/journal.pcbi.1003107
33. Shi R, Li Y, Liu H, Chen J. Lung microbiota: Unexploited treasure hidden in the immune microenvironment of lung cancer. Thorac Cancer. 2021;12(21):2964-6. DOI: 10.1111/1759-7714.14159
34. Sisti J, Boffetta P. What proportion of lung cancer in never-smokers can be attributed to known risk factors? Int J Can-cer. 2012;131(2):265-75. DOI: 10.1002/ijc.27477
35. Stella GM, Scial? F, Bortolotto C, et al. Pragmatic Ex-pectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review. Cancers (Basel). 2022;14(13):3131. Published 2022 Jun 26. DOI: 10.3390/cancers14133131
36. Tsay JJ, Wu BG, Badri MH, et al. Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Can-cer. Am J Respir Crit Care Med. 2018;198(9):1188-98. DOI: 10.1164/rccm.201710-2118OC
37. Wang D, Cheng J, Zhang J, et al. The Role of Respiratory Microbiota in Lung Cancer. Int J Biol Sci. 2021;17(13):3646-58. Published 2021 Aug 25. DOI: 10.7150/ijbs.51376
38. Wong JYY, Zhang H, Hsiung CA, et al. Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. Genomics. 2020;112(2):1223-32. DOI: 10.1016/j.ygeno.2019.07.008
39. Xu N, Wang L, Li C, et al. Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms. Transl Lung Cancer Res. 2020;9(4):1554-68. DOI: 10.21037/tlcr-20-156
40. Yagi K, Huffnagle GB, Lukacs NW, Asai N. The Lung Microbiome during Health and Disease. Int J Mol Sci. 2021;22(19):10872. Published 2021 Oct 8. DOI: 10.3390/ijms221910872
41. Yu YH, Liao CC, Hsu WH, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol. 2011;6(1):32-7. DOI: 10.1097/JTO.0b013e3181fb4fcc
42. Zeng W, Zhao C, Yu M, et al. Alterations of lung microbiota in patients with non-small cell lung cancer. Bioengi-neered. 2022;13(3):6665-77. DOI: 10.1080/21655979.2022.2045843
43. Zhuo M, An T, Zhang C, Wang Z. Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients. Front Oncol. 2020;10:1584. Published 2020 Aug 24. DOI: 10.3389/fonc.2020.01584
44. Zitvogel L, Kroemer G. Lower Airway Dysbiosis Exacerbates Lung Cancer. Cancer Discov. 2021;11(2):224-6. DOI: 10.1158/2159-8290.CD-20-1641
45. Arseniev AI, Nefedova AV, Ganeev АА, et al. Combined diagnostics of lung cancer using exhaled breath analsysis and sputum cytology. Oncology issues. 2020;66(4):381-4. (In Russ).
46. Martirosova KM, Zhandarova LF, Matveyeva OV. Рossibilities of cytological research method in the diagnosis of lung tumors. Medicus. 2020;4(34):32-40. (In Russ).
47. Rodionov EO, Tuzikov SA, Miller SV., et al. Methods for early detection of lung cancer (review). Siberian journal of oncology. 2020;19(4):112-22. (In Russ).
48. Filimonova ES, Tarasenko SL, Dykhno YuA., et al. Evaluation of efficiency the cytological diagnosis of malignant lung neoplasms. Siberian Medical Review. 2014;3(87):65-9. (In Russ).

The article can be purchased
electronic!

PDF format

Free

DOI: 10.14489/lcmp.2022.04.pp.051-058
Article type: Review
Make a request

Keywords

microbiome, lung microbiota, lung cancer, oncology, cytopathology.

Use the reference below to cite the publication

Kireev AA, Gorbanev AI. The pulmonary microbiome as a risk factor for lung cancer development and progression. Review. Laboratory and Clinical Medicine. Pharmacy. 2022;2(4):51-58. (In Russ). DOI: 10.14489/lcmp.2022.04.pp.051-058

Баннер снизу

Editor-in-chief

 

Zhanna Yu. Sapozhkova

Journal of the International  Cytology School and  Innovatory Medical School

Journal of the International  Cytology School and  Innovatory Medical School